Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 4/1/2024

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

featured
Published in Oncology

Expert Opinion / Conference Coverage · February 01, 2024

ASCO GU 2024: Bladder Cancer Highlights

Written by
Guru P. Sonpavde MD

 

Additional Info

  1. Apolo AB, Ballman KV, Sonpavde GP, et al. AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract LBA531.
  2. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114.
  3. Van Der Heijden MS, Powles T, Sonpavde G, et al. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract LBA530.
  4. Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218-1230.
  5. U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma [press release]. Princeton, NJ: Bristol Myers Squibb; December 5, 2023.
  6. Van Der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778-1789.
  7. Jain RK, Swami U, Bilen MA, et al. Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab). Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract 539.
  8. Galsky MD, Sfakianos JP, Ye D, et al. Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract 632.
  9. Lisberg A, Drakaki A, Meric-Bernstam F, et al. Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION PanTumor01 study. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract 603.
  10. Jain RK. Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs). study. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract 625.
  11. Roda D, Machiels J-PH, Chiu C-F, et al. Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort. Paper presented at: 2024 ASCO Genitourinary Cancers Symposium; January 25–27, 2024; San Francisco, CA. Abstract 617.

Disclosure statements are available on the authors' profiles:

Further Reading